How to Counsel ADHD Medication Use During Pregnancy
How should clinicians counsel a pregnant patient about continuing stimulant versus nonstimulant ADHD medication?
Pregnant patients with attention-deficit/hyperactivity disorder may have worsening symptoms if treatment is stopped, but they also face uncertain obstetric risk if medication is continued. This guide applies when a clinician is weighing stimulant treatment, nonstimulant treatment, or no ADHD medication during pregnancy and needs to frame a risk-benefit discussion using the findings of Obstetric Risk Associated With Stimulant Versus Nonstimulant Treatment During Pregnancy.
-
Confirm the exposure pattern under discussion
Clarify whether the patient is currently using a stimulant, a nonstimulant, or neither during pregnancy, because the study compared these 3 mutually exclusive exposure patterns. In the study, medication exposure meant 2 or more electronic health record medication records during pregnancy for a stimulant or nonstimulant class, with no records from the opposite class.
-
Review baseline factors that also influence obstetric risk
Before discussing medication-specific risk, review the patient’s age, race and ethnicity, smoking or drinking status, and comorbid obesity or overweight, hypertension, depression, anxiety, bipolar disorder, ADHD, and substance use disorder. These were the measured baseline characteristics the study accounted for because women prescribed stimulant or nonstimulant medication had higher rates of medical and psychiatric adversity than the no-medication group.
-
Explain that both medication classes were associated with elevated obstetric risk versus no medication
Tell patients that in this observational cohort, both stimulant and nonstimulant exposure during pregnancy were associated with increased risk for multiple obstetric outcomes after adjustment for measured baseline differences. For stimulants versus no medication, increased-risk odds ratios ranged from 1.21 for large for gestational age to 1.85 for gestational hypertension and placenta previa, while there was no significant effect for gestational diabetes.
-
Describe the nonstimulant risk pattern without assuming it is safer
Explain that nonstimulant exposure was also associated with significantly higher risk for most obstetric outcomes compared with no medication. The reported increased-risk odds ratios ranged from 1.12 for gestational diabetes and placenta previa to 5.70 for placental abruption, and nonstimulants were associated with increased risk for gestational hypertension, preeclampsia or eclampsia, IUGR, preterm delivery, and spontaneous abortion.
-
Use head-to-head differences to individualize the choice between stimulant and nonstimulant treatment
If the decision is specifically stimulant versus nonstimulant treatment, explain that neither class was uniformly lower risk across all outcomes. Compared with nonstimulants, stimulants had higher odds of placenta previa and large for gestational age but lower odds of gestational diabetes, placental abruption, intrauterine growth restriction, and preterm delivery, with no significant differences in gestational hypertension, preeclampsia or eclampsia, or spontaneous abortion.
-
Make the final plan through shared decision-making
Frame the decision as an individualized risk-benefit choice that weighs possible maternal functioning benefits against the observed obstetric risk signals. The authors specifically emphasize person-centered counseling and shared decision-making rather than treating these observational findings as definitive causal safety estimates.
Clinical Considerations
- This was an observational electronic health record study, so the findings are signal-detection evidence rather than definitive causal safety estimates.
- Inverse probability of treatment weighting reduced confounding from measured baseline factors only, and residual confounding from unmeasured factors may remain.
- Medication exposure was defined by 2 or more electronic health record medication records during pregnancy and does not establish adherence, continuous use, or exact timing of exposure.
- The nonstimulant group was small and clinically heterogeneous, and the study could not determine specific indications for many nonstimulant prescriptions.
Bottom Line
Do not assume nonstimulant ADHD medication is the safer pregnancy option; both stimulant and nonstimulant exposure were associated with elevated obstetric risk, so counseling should be individualized and outcome-specific.
